Company Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States.
It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations.
The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer.
Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
| Country | Canada |
| Founded | 2016 |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 179 |
| CEO | Lloyd Mitchell Segal |
Contact Details
Address: 7171 Frederick Banting, Suite 270, Building 2 Saint-laurent, A8 H4S 1Z9 Quebec, Canada | |
| Phone | (857) 412-7018 |
| Website | reparerx.com |
Stock Details
| Ticker Symbol | RPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001808158 |
| CUSIP Number | 760273102 |
| ISIN Number | US7602731025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Mitchell Segal | President, Chief Executive Officer and Director |
| Dr. Michael Zinda Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Maria Koehler M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Steve Forte | Executive Vice President and Chief Financial Officer |
| Daniel Belanger | Executive Vice President of Human Resource |
| Cameron Black | Executive Vice President of Discovery |
| Dr. Kim A. Seth Ph.D. | Executive Vice President and Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2024 | 144 | Filing |
| Mar 26, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Mar 25, 2024 | 144 | Filing |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |